Share of priority review drug approval applications treating cancer
RecordSTO-GGARQ2TA60-APCABM5RN7-FZXZJ9
China · 1 Jan 2020 to 20 Mar 2025
Share of priority review drug approval applications treating cancer in China was 42.5% between 1 January 2020 and 20 March 2025 (State Council).
- Publisher
- State Council
- Authority tier
- T1 Official
- Retrieved
- 17 Sep 2026
- Status
- Verified
What the source says
Since China updated its drug registration and administrative rules in 2020, 496 drug approval applications have been placed under the priority review program, with 42.54 percent treating cancer.
Checked: the figure 42.5%is stated in this passage. If it does not match, the extraction is wrong and we want to know.
Cite this figure
APA
State Council of China. (2025). Measures facilitate approval of 48 first-in-class innovative drugs. Retrieved September 17, 2026, from https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html. Via StatOrigin, https://statorigin.org/stat/stat_GGARQ2TA60APCABM5RN7FZXZJ9
Other formats: MLA, Chicago, BibTeX
- MLA
- State Council of China. "Measures facilitate approval of 48 first-in-class innovative drugs." 2025, https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html. Accessed 17 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_GGARQ2TA60APCABM5RN7FZXZJ9.
- Chicago
- State Council of China. "Measures facilitate approval of 48 first-in-class innovative drugs." 2025. https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html. Accessed September 17, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_GGARQ2TA60APCABM5RN7FZXZJ9.
- BibTeX
- @misc{statecouncil2025sharefzxzj9, author = {{State Council of China}}, title = {Measures facilitate approval of 48 first-in-class innovative drugs}, year = {2025}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_GGARQ2TA60APCABM5RN7FZXZJ9}, note = {Original source: https://english.www.gov.cn/news/202503/20/content\_WS67db7e91c6d0868f4e8f0fd6.html. Accessed September 17, 2026.} }
Data published under CC BY 4.0. The citation credits the original publisher and links to this permanent record.
Provenance and verification
Everything needed to check this number yourself, without taking our word for it.
Primary source
- Publisher
- State Council of China · homepage ↗
- Authority tier
- Tier 1 · Multilateral Official
- Report
- Measures facilitate approval of 48 first-in-class innovative drugs
- Type
- Press release
- Published
- —
- Locator
- Measures facilitate approval of 48 first-in-class innovative drugs
- Retrieved
- 17 September 2026
- Link status
- Reachable (HTTP 200)
- Report licence
- See source
Verification
- Status
- Verified
- Review protocol
- editorial:judge-fix-v1:2026-09-27
- Checked on
- 27 September 2026
- Last revision
- 27 September 2026
- Permanent URL
- /stat/stat_GGARQ2TA60APCABM5RN7FZXZJ9